Uncovering the biochemical mechanisms underlying different types of cell death has the potential to provide targets for the treatment of various diseases. A physiological cytokine combination ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Autoimmune diseases stem from a complicated interplay of immune dysregulation, characterized by chronic inflammation and the loss of self-tolerance. Cytokines are central to these processes. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results